Добірка наукової літератури з теми "Diabète de type 2 – chirurgie"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Diabète de type 2 – chirurgie".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Diabète de type 2 – chirurgie":
Amouyal, C., and F. Andreelli. "Chirurgie métabolique du diabète de type 2." Médecine des Maladies Métaboliques 9, no. 5 (July 2015): 473–81. http://dx.doi.org/10.1016/s1957-2557(15)30200-5.
Jaffiol, Claude, and Patrick Ritz. "Chirurgie métabolique et diabète de type 2." Bulletin de l'Académie Nationale de Médecine 196, no. 7 (October 2012): 1473–75. http://dx.doi.org/10.1016/s0001-4079(19)31729-7.
D, Y. M. "Chirurgie bariatrique : un traitement du diabète de type 2." Option/Bio 25, no. 518 (December 2014): 10. http://dx.doi.org/10.1016/s0992-5945(14)72015-x.
Jean-Marie, Manus. "Chirurgie bariatrique, un traitement du diabète de type 2." Revue Francophone des Laboratoires 2024, no. 563 (2024): 13. http://dx.doi.org/10.1016/s1773-035x(24)76112-7.
D, Y. M. "La chirurgie bariatrique pour guérir le diabète de type 2." Option/Bio 26, no. 533 (November 2015): 11. http://dx.doi.org/10.1016/s0992-5945(15)30319-6.
M, J. M. "La chirurgie de l’obésité neutralise le diabète de type 2." Revue Francophone des Laboratoires 2009, no. 417 (December 2009): 12. http://dx.doi.org/10.1016/s1773-035x(09)70289-8.
A, F. "Chirurgie bariatrique et diabète de type 2 : effets permanents ou temporaires ?" Médecine des Maladies Métaboliques 10, no. 6 (October 2016): 581. http://dx.doi.org/10.1016/s1957-2557(16)30174-2.
Laurian, Claude. "Chirurgie bariatrique : impact sur la stratégie thérapeutique (obésité – diabète de type 2)." Sang thrombose vaisseaux 24, no. 5 (May 2012): 207–9. http://dx.doi.org/10.1684/stv.2012.0704.
Andreelli, F., and P. Ritz. "Vers de nouvelles recommandations pour la chirurgie du diabète de type 2 ?" Médecine des Maladies Métaboliques 12, no. 2 (March 2018): 168–73. http://dx.doi.org/10.1016/s1957-2557(18)30042-7.
Plas, C., F. Dalmay, S. Nassouri, A. Drutel, S. Galinat, P. Vital, C. Peyronnet, et al. "Chirurgie bariatrique : quelle technique choisir pour guérir le diabète de type 2 ?" Annales d'Endocrinologie 78, no. 4 (September 2017): 299. http://dx.doi.org/10.1016/j.ando.2017.07.229.
Дисертації з теми "Diabète de type 2 – chirurgie":
Plourde, Charles-Étienne. "Les mécanismes de résolutions du diabète de type 2 induits par la chirurgie bariatrique." Mémoire, Université de Sherbrooke, 2015. http://hdl.handle.net/11143/6038.
Maanaoui, Mehdi. "La greffe d'îlots pancréatiques chez le patient diabétique transplanté rénal." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. https://pepite-depot.univ-lille.fr/ToutIDP/EDBSL/2023/2023ULILS071.pdf.
Pancreatic islet transplantation is an innovative cellular therapy for the management of diabetes in patients with type 1 diabetes. Currently, there are few studies that address the prognostic impact of islet transplantation in patients with type 1 diabetes who have received a kidney transplant or the determinants of transplantation success in this population. Furthermore, the definition of diabetes is evolving, with the dichotomy between type 1 and type 2 diabetes fading in favor of diabetes classifications based on the patient's clinical and biological phenotype. Pancreatic islet transplantation could potentially be expanded to other profiles of patients with diabetes and a kidney transplant, especially if there's evidence of insulin secretion deficiency. Thus, the objective of this thesis is to determine the role of pancreatic islet transplantation in patients with diabetes and a kidney transplant.In the first section, we present the results of a nationwide cohort study assessing the effect of pancreatic islet transplantation following kidney transplantation compared to insulin alone in patients with type 1 diabetes. Islet-after-kidney recipients were matched to control patients using a time-dependent propensity score. After matching, pancreatic islet transplantation is associated with a reduction in the combined risk of death and return to dialysis, as well as the isolated risk of death. This study emphasizes the importance of considering islet transplantation as a full-fledged therapeutic alternative, especially in regions where it is not reimbursed or available.The second section explores the determinants of islet loss of functionality, in particular the repercussions of alloimmunity. The results of a single-center study suggest that preformed DSA and early de novo DSA have little impact on islet transplantation outcomes, but late de novo DSA is temporally associated with impaired metabolic results. No cases of cross-sensitization between pancreatic islets and the underlying kidney in recipients were described, neither in the study nor in the literature.The last section focuses on evaluating the insulin profile in patients with type 2 diabetes and a kidney transplant, through the calculation of HOMA-2 scores, to extract the impact of insulin secretion. Analysis of a single-center retrospective cohort shows an association between insulin resistance evaluated by HOMA-2 and the risk of allograft loss, while insulin secretion was only associated with metabolic balance. However, given the relationship between metabolic balance and the likelihood of death and graft loss in kidney transplant patients with diabetes, pancreatic islet transplantation could be part of the therapeutic arsenal in a personalized medicine approach for these patients.In conclusion, this thesis advocates for personalized diabetes medicine in kidney transplant patients, promoting the integration of pancreatic islet transplantation as a key component in the therapeutic strategy for these individuals
Favennec, Marie. "Etude de la voie des kynurénines dans l'obésité humaine." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S037/document.
Tryptophan, an essential amino acid, is either used in protein synthesis or metabolized via the serotonin or the kynurenine pathway. The kynurenine pathway is the main route of tryptophan degradation and generates several metabolites collectively called “kynurenines”. The expression of kynurenine pathway enzymes is induced by inflammatory mediators. Consequently kynurenine synthesis could be induced in individuals with obesity. In fact, obesity is characterized by a chronic low grade inflammation of the adipose tissue reflected by increased serum levels of inflammatory factors which are known to contribute to the development of obesity-induced insulino-resistance. Some metabolites of the kynurenine pathway have been proposed to be risk factors for the development of insulin resistance. Bariatric surgery is currently the most effective treatment for severe obesity and results in a significant weight loss, a decreased level of inflammatory factors and an amelioration of glucose homeostasis. The first enzyme of the kynurenine pathway, IDO1, is known to be more expressed in the adipose tissue of individuals with obesity compared to lean individuals. The kynurenine over tryptophan ratio reflects the activity of IDO1 and is also increased in individuals with obesity.Our objective was to characterize the expression of the kynurenine pathway enzymes in the adipose tissue of women with severe obesity and to evaluate serum levels of the kynurenine pathway metabolites to determine whether these factors could be associated with the appearance of diabetes. This study was performed in women with severe obesity with or without type 2 diabetes. Then we investigated the consequences of weight loss induced by bariatric surgery on levels of circulating kynurenines in order to evaluate whether these variations could explain the improvement in glucose control and type 2 diabetes remission after one year follow-up.In this study, we have shown that several kynurenine pathway enzymes were more expressed in the adipose tissue of women with obesity compared to lean controls. This increase is due to the presence of pro-inflammatory macrophages in the adipose tissue and also comes from the adipocyte response to inflammatory stimuli. In addition, we observed that the serum level of kynurenine and kynurenine over tryptophan ratio are higher in women with higher BMI and they both decrease one year after bariatric surgery. In addition, we observed that the serum level of kynurenine and kynurenine over tryptophan ratio are higher in women with higher BMI and they both decrease one year after bariatric surgery. As expected, bariatric surgery is associated with the improvement and even the remission of type 2 diabetes. We have shown that higher levels of kynurenic acid and quinolinic acid one year after the surgery are associated respectively with type 2 diabetes remission and better glucose homeostasis and that lower levels of xanthurenic acid are associated with better glucose homeostasis
Arapis, Konstantinos. "Mise au point de modèles précliniques de chirurgie bariatrique chez le rat rendu obèse par un régime hyperlipidique." Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCC086.
Chavez, Talavera Oscar Manuel. "Rôle des acides biliaires dans la physiopathologie de l'obésité, la résistance à l'insuline, le diabète de type 2, la stéatose hépatique non alcoolique et dans le contexte de la chirurgie bariatrique Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease Bile Acid Alterations in Nonalcoholic Fatty Liver Disease, Obesity, Insulin Resistance and Type 2 Diabetes: What Do the Human Studies Tell?” Bile acids associate with glucose metabolism, but do not predict conversion to diabetes Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs The functional relevance of bile acids in the improvement of HDL-mediated endothelial protection after bariatric surgery Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors." Thesis, Lille, 2019. http://www.theses.fr/2019LILUS057.
In addition to their role in the solubilization of dietary lipids, bile acids are signaling molecules regulating their own metabolism, glucose and lipid homeostasis, energy expenditure, cardiovascular function and inflammation via the activation of the Farnesoid X Receptor (FXR) and the Takeda G protein coupled Receptor 5 (TGR5). Indeed, changes in bile acid concentrations are associated with metabolic diseases and therefore they are candidates to participate in the pathophysiology of these diseases or predict their progression.In the first part of this thesis, we studied bile acid changes in the context of obesity, insulin resistance, type 2 diabetes and non-alcoholic steatohepatitis. We demonstrated that bile acids are correlated with glucose homeostasis in humans, but that they are not predictors for the progression from prediabetes to type 2 diabetes in a longitudinal cohort study.In the second part of this thesis, we studied the bile acids in the context of bariatric surgery. Our results showed that bariatric surgery reduces the hepatic recapture of certain bile acids, causing them to increase in the systemic circulation. Additionally, we showed that it is not the bile limb but the common limb the one responsible for metabolic changes after bariatric surgery in the minipig. Finally, we showed in humans that bile acids linked to high-density lipoproteins (HDL) increase after bariatric surgery, and that this increase is correlated with the restoration of their vasoprotective functions
Goncalves, Daisy. "Biodisponibilité de la bile et effets bénéfiques des chirurgies bariatriques de type by-pass." Thesis, Lyon 1, 2014. http://www.theses.fr/2014LYO10171/document.
Gastric bypass procedures have emerged as an effective treatment for morbid obese diabetic patientssince they provoke a rapid remission of diabetes before any weight loss has occurred. Patients also report adisinterest in high calorie food. A suggested mechanism associated a decrease in hepatic glucose production toan enhanced intestinal gluconeogenesis. Bile acids, described as inhibitors of gluconeogenesis, see theirbioavailability changed after these procedures. Indeed, they are absent in the alimentary limb while theirplasmatic concentration is increased. We therefore tested the hypothesis that plasma bile acids may inhibithepatic glucose production while their absence in the gut could induce intestinal gluconeogenesis.For this, we performed bile diversions matching the modified biliary flow occurring after gastric bypassprocedures. We showed that bile diversions lead to an increase in plasma bile acids. Bile diversions promote ablunting in hepatic glucose production whereas intestinal gluconeogenesis is increased in gut segments devoidof bile. Moreover, the modification of bile routing per se improves glucose control and dramatically decreasefood intake due to an acquired disinterest in fatty food. This data shows that bile routing modification is a keymechanistic feature in the beneficial outcomes of gastric bypass procedures
Spinelli, Valeria. "Les acides biliaires et la régulation de l’homéostasie métabolique : rôle du récepteur Farnesoid X Receptor (FXR) dans la cellule bêta-pancréatique : variation du pool des acides biliaires et chirurgie bariatrique Roux-en-Y Gastric Bypass." Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S054.
Bile acids (BAs) are molecules produced in the liver, stored in the gallbladder, secreted into the intestine and returning to the liver via the enterohepatic circulation. A fraction of BAs escapes the reuptake by the liver and enters the systemic circulation, by which they reach the peripheral organs including the pancreas. Besides their function in facilitating the intestinal absorption of lipids, BAs are signaling molecules that act through receptors for BAs, which are expressed in the key tissues for metabolic regulation, and whose modulation by BAs contribute to regulate energy homeostasis. Thus, variations in the composition of the BAs pool determine the modulation of metabolism via their receptors. The BA-receptor Farnesoid-X receptor (FXR) is involved in the regulation of glucose, lipid and BA metabolism by its action in the liver, intestine, adipose tissue and pancreas. Whole body FXR deficient mice are glucose intolerant and insulin resistant in liver and peripheral tissues, whereas in a context of obesity, FXR deficiency rather improves these parameters. Furthermore, FXR is expressed in the pancreatic beta cell (bcell), where it regulates the synthesis and the secretion of insulin, but the molecular mechanisms have not been fully elucidated yet. To understand 1) the contribution of FXR bcell in the metabolic phenotype of the total FXRKO-mouse, and 2) the molecular mechanisms of the regulation of insulin production by FXR in the bcell, I developed a mouse model invalidated for FXR specifically in the bcell by the Cre-loxP strategy. The development of the model showed nonspecific recombination phenomena, and I developed a genotyping strategy to overcome this problem. To highlight the phenotype of the FXRKObcell mouse I tested various metabolic contexts (standard and high fat diet, fasting and refeeding conditions, circadian variations). Compared to control, FXRKO-bcell mice developed glucose intolerance and has lower insulinémia, defects increased by a high fat diet. The global transcriptomic analysis in the islets identified a set of microRNA strongly deregulated by invalidating FXR in the bcell, which could explain the dysfunctions in insulin secretion. Besides the modulation of the activity of the receptors, metabolic effects can be obtained by varying the composition of the pool of their ligands BAs. Thus, metabolic perturbations (such as insulin resistance and type 2 diabetes, obesity) are associated with qualitative and/or quantitative variations in the BA pool. In addition, variations of the BAs pool are associated to the metabolic improvement that precedes the weight loss after the surgical practice of Roux-en-Y Gastric Bypass (RYGB), which suggests that the BAs can be among the actors of the ‘weight loss-indipendent’ beneficial metabolic effects of RYGB. To investigate this hypothesis, some preclinical models of RYGB have been developed. During my thesis I compared the pool of BAs pre and post RYGB among three species (rat, pig and human; Coll. Prof. F. Pattou and Dr. E.Osto) with the aim of assessing which preclinical model is most suitable for these studies in terms of characteristics of the BAs pool. In a second study, I focused on the causes and mechanisms underlying the increased concentrations of circulating BAs induced by RYGB. In the model of minipig (coll. Pr. F. Pattou), the analysis of the plasma BA pool composition and the hepatic gene expression before and after RYGB, allowed to show that changes in the hepatic function are - at least in part - responsible for the increase of the BA pool following RYGB
Baud, Grégory. "Modulation de l’absorption intestinale postprandiale du glucose apès Roux-en-Y Gastric Bypass chez le miniporc." Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S042/document.
Type 2 diabetes (T2D) is characterized primarily as a combined defect of insulin secretion and insulin action. For nearly a decade, the somewhat mysterious but spectacular benefit of metabolic surgery, and more specifically of Roux-en-Y gastric bypass (RYGB), on glucose control has been caused a questioning the current paradigm of T2D management. Gastro-intestinal exclusion by RYGB improves glucose metabolism, independent of weight loss. Although changes in intestinal bile trafficking have been shown to play a role, the underlying mechanisms are unclear. We performed RYGB in minipigs and showed that the intestinal uptake of ingested glucose is blunted in the bile deprived alimentary limb (AL). Glucose uptake in the AL was restored by the addition of bile, and this effect was abolished when active glucose intestinal transport was blocked with phlorizin. Sodium-glucose cotransporter 1 remained expressed in the AL, while intraluminal sodium content was markedly decreased. Adding sodium to the AL had the same effect as bile on glucose uptake. It also increased postprandial blood glucose response in conscious minipigs following RYGB. The decrease in intestinal uptake of glucose after RYGB was confirmed in humans. Our results demonstrate that bile diversion affects postprandial glucose metabolism by modulating sodium-glucose intestinal cotransport
Barataud, Aude. "Rôle de la néoglucogenèse intestinale et des récepteurs mu-opioïdes dans les effets bénéfiques du by-pass gastrique chez la souris." Thesis, Lyon 1, 2014. http://www.theses.fr/2014LYO10276/document.
Roux-en-Y gastric bypass procedure (GBP) is an obesity surgery that induces dramatic glucose homeostasis improvements independently of weight loss. A proposed mechanism to explain these glucose homeostasis improvements is an increase in intestinal glucose production (IGP) that induces beneficial effects on metabolism (satiety, improved liver insulin sensitivity). This increase in IGP is found in mice that have undergone a simplified GBP and is also responsible for the beneficial effects of protein-enriched diets through the inhibition of mu-opioid receptors (MOR) by alimentary peptides. We therefore hypothesized that the beneficial effects of GBP could depend on MOR inhibition by dietary proteins and we also tested the causal role of IGP in these metabolic improvements. For this purpose, we performed a duodenal-jejunal bypass surgery (DJB), ie GBP without gastric restriction, in wild-type mice (WT), in mice lacking MOR gene (MOR-/-) and in mice lacking IGP (IG6pc-/-). In obese mice, DJB induced a rapid and substantial weight loss (-30%), partly explained by fat malabsorption, and weight loss-dependent improvements of glucose homeostasis. In contrast, in the non-obese mice, DJB did not induce weight loss nor malabsorption but improved glucose tolerance. Effects were similar in WT, MOR-/- and I-G6pc-/- mice showing that mu-opioid receptors and IGP did not appear to have a causal role in glucose and energy metabolism improvements after DJB
St-Yves, Annie. "Diabète gestationnel : le risque et la prévention du diabète de type 2." Thesis, Université Laval, 2012. http://www.theses.ulaval.ca/2012/28802/28802.pdf.
Women with prior gestational diabetes (GDM) are at risk of type 2 diabetes (T2D). Weight gain during childbearing-age period was associated with deteriorated insulin sensitivity and higher risk of T2D among women with prior GDM of our study. Healthy eating was not optimal in order to prevent T2D among these women. Application of the theory of planned behavior suggest that an intervention to increase intention to adopt healthy eating among women with prior GDM would need to focus on straightening the perception of its beneficial effect on weight control and on providing information on healthy eating and coping with availability of non-healthy foods in order to prevent future development of T2D among these women.
Книги з теми "Diabète de type 2 – chirurgie":
Young, Carolyn. Diabète de type 2. Outremont, Québec: Quebecor, 2003.
Mallette, Yves. Solutions au diabète de type 2. Montréal: Éditions Québecor, 2007.
Guillausseau, Pierre-Jean. Le diabete de type 2. Paris: Ellipses, 2003.
Massey, Robert. Lutter contre le diabète de type 2. Montréal: Éditions Québecor, 2008.
Graham, Karen. The complete diabetes guide for type 2 diabetes. 2nd ed. Portage la Prairie, Man: Paper Birch Pub., 2011.
Webb, Karen. Body basics for type 2 diabetes: The cornerstones of diabetes management! Thornbury, Ont: Birchcliff Pub., 2004.
Rosenthal, M. Sara. Managing your diabetes: The only complete guide to type 2 diabetes for Canadians. Toronto: Macmillan Canada, 1998.
Karen, Bellenir, ed. Diabetes sourcebook: Basic consumer health information about type 1 diabetes (insulin-dependent or juvenile-onset diabetes), Type 2 diabetes (noninsulin-dependent or adult-onset diabetes), gestational diabetes, and related disorders... 2nd ed. Detroit, MI: Omnigraphics, 1999.
Association, American Diabetes. A field guide to type 2 diabetes: The essential resource from the diabetes experts. Alexandria, VA: American Diabetes Association, 2004.
Gerson, Michel, and (Association AFD. Le diabète de type 2. ELLIPSES, 2012.
Частини книг з теми "Diabète de type 2 – chirurgie":
Ecochard, Aude Mariani. "Diabète de type 2." In Endocrinologie de l’adolescent, 71–77. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0322-7_7.
Ecochard, Aude Mariani. "Diabète de type 1." In Endocrinologie de l’adolescent, 49–70. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0322-7_6.
Pfaff, Daniel. "Fall 44: Bariatrische Chirurgie – 58 Jahre, ♂, DM Typ 2, Sleeve-Gastrektomie." In Diabetes-Therapie – informiert entscheiden, 175–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-55972-7_44.
Mariani Ecochard, Aude. "Diabète insulinodépendant de type 1 : Prise en charge au diagnostic." In Endocrinologie de l’adolescent, 173–82. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0326-5_27.
Pfaff, Daniel. "Fall 72: Bariatrische Chirurgie – 61 Jahre, ♂, DM Typ 2, Übergewicht, koronare Herzerkrankung, Albuminurie." In Diabetes-Therapie – informiert entscheiden, 289–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-55972-7_72.
Pfaff, Daniel. "Fall 45: Bariatrische Chirurgie – 63 Jahre, ♀, DM Typ 2, Übergewicht, Schlafstörung durch Muskelkrämpfe und Kribbeln." In Diabetes-Therapie – informiert entscheiden, 179–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-55972-7_45.
Himpens, Jacques, Giovanni Dapri, and Patrick Van Alphen. "Critères de choix : une technique pour tous les patients ou bien une modulation selon le type de patient?" In Chirurgie de l’obésité, 75–88. Paris: Springer Paris, 2009. http://dx.doi.org/10.1007/978-2-287-79954-9_6.
Otto, G., J. U. Bleyl, L. Theilmann, R. Roeren, W. J. Hofmann, and Ch Herfarth. "2-Jahres-Ergebnisse bei der Therapie von „Ischemic Type Lesions“ nach Lebertransplantation." In Deutsche Gesellschaft für Chirurgie, 79–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-79242-7_21.
"Diabète de type 2." In Méga Guide STAGES IFSI, 528–31. Elsevier, 2015. http://dx.doi.org/10.1016/b978-2-294-74529-4.00165-8.
Alexandre, J., A. Balian, L. Bensoussan, A. Chaïb, G. Gridel, K. Kinugawa, F. Lamazou, et al. "Diabète de type 2." In Le tout en un révisions IFSI, 477–80. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70633-2.50164-5.
Тези доповідей конференцій з теми "Diabète de type 2 – chirurgie":
Sandforth, Leontine, Erminia Lembo, Ornella Verrastro, Arvid Sandforth, Karin Zhou, Rami Archid, Robert Wagner, et al. "Risikoclusterbasierte Vorteile bariatrischer Chirurgie für Menschen mit hohem Risiko für Diabetes mellitus Typ 2." In Diabetes Kongress 2023 - 57. Jahrestagung der DDG. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1767893.
Sandforth, Leontine, Violeta Raverdy, Arvid Sandforth, Pierre Bauvin, Marlene Ganslmeier, Estelle Chatelain, Robert Wagner, et al. "Subphänotyp-abhängige Effekte bariatrischer Chirurgie in datengestützten Clustern von Menschen mit erhöhtem Risiko für Typ-2-Diabetes." In Diabetes. Umwelt. Leben. Perspektiven aus allen Blickwinkeln. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1785369.
Laubner, Katharina, Angeliki Pappa, Anton Gillesen, Marcus Altmeier, Petra Augstein, Sebastian Meyhöfer, Julia K. Mader, et al. "Bariatrische Chirurgie bei Menschen mit Diabetes mellitus Typ 1 oder 2 – eine multizentrische Analyse der DPV-Wiss-Datenbank." In Diabetes. Umwelt. Leben. Perspektiven aus allen Blickwinkeln. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1785344.
Nikiforova, L., N. Sapundzhiev, D. Krumova, B. Spasova, and G. Davidov. "Diagnostic value of the static laryngeal image in laryngomalacia type 1, 2 and 3." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1711317.
Elmoutawakkil, N., S. Bouzoubaa, S. Bellemkhannate, and I. Benyahya. "Flux de travail du guidage tridimensionnel en chirurgie orale." In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206602005.
Ceddaha Zibi, A. "Migraine faciale à expression dentaire, à propos de trois cas." In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603016.
Baranes, M., and T. Fortin. "Planification et chirurgie guidée - Avis d’experts : Apports des nouvelles technologies en implantologie : de la planification à la réalisation de la prothèse provisoire immédiate." In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206601011.
Nayl, C., M. Fenelon, S. Catros, and J. C. Fricain. "Hémangioendothéliome intravasculaire végétant lingual : à propos d’un cas." In 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603004.